ZULRESSO for Treating Postpartum Depression Launched by Sage

Ligand Pharmaceuticals Inc. (NASDAQ: LGND) today announced that SAGE Therapeutics has launched ZULRESSO™ (brexanolone) injection, which was approved by the U.S. Food and Drug Administration (FDA) on March 19, 2019, and is the first and only treatment specifically approved for postpartum depression (PPD), one of the most common medical complications during and after pregnancy. ZULRESSO uses Ligand’s Captisol in its formulation. With this launch, ZULRESSO is the 11th FDA-approved drug to use Ligand’s patented Captisol technology.

ZULRESSO is administered via continuous intravenous (IV) infusion for 2.5 days under the supervision of healthcare providers in sites of care certified under the ZULRESSO Risk Evaluation and Mitigation Strategy (REMS) program. For more information on ZULRESSO, including the final product label, visit ZULRESSO.COM or ZULRESSOREMS.COM.

https://www.biospace.com/article/releases/zulresso-brexanolone-civ-a-product-for-treating-postpartum-depression-using-ligand-s-captisol-in-its-formulation-launched-by-sage-therapeutics/